Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies
The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose...
Saved in:
| Published in: | European journal of pharmacology Vol. 978; p. 176803 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
05.09.2024
|
| Subjects: | |
| ISSN: | 0014-2999, 1879-0712, 1879-0712 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the context of BC. Preclinical studies have demonstrated that various SGLT2 inhibitors, such as canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, can inhibit the proliferation of BC cells, induce apoptosis, and modulate key cellular signaling pathways. These mechanisms include the activation of AMP-activated protein kinase (AMPK), suppression of mammalian target of rapamycin (mTOR) signaling, and regulation of lipid metabolism and inflammatory mediators. The combination of SGLT2 inhibitors with conventional treatments, including chemotherapy and radiotherapy, as well as targeted therapies like phosphoinositide 3-kinases (PI3K) inhibitors, has shown promising results in enhancing the anti-cancer efficacy and potentially reducing treatment-related toxicities. The identification of specific biomarkers or genetic signatures that predict responsiveness to SGLT2 inhibitor therapy could enable more personalized treatment selection and optimization, particularly for challenging BC subtypes [e, g., triple negative BC (TNBC)]. Ongoing and future clinical trials investigating the use of SGLT2 inhibitors, both as monotherapy and in combination with other agents, will be crucial in elucidating their translational potential and guiding their integration into comprehensive BC care. Overall, SGLT2 inhibitors represent a novel and promising therapeutic approach with the potential to improve clinical outcomes for patients with various subtypes of BC, including the aggressive and chemo-resistant TNBC.
[Display omitted]
•SGLT2 inhibitors have shown anti-cancer properties in breast cancer treatment.•Specific SGLT2 inhibitors have demonstrated the ability to inhibit breast cancer cell proliferation.•SGLT2 inhibitors have been found to induce apoptosis in breast cancer cells, potentially contributing to tumor reduction.•These inhibitors have shown a potential to enhance the effectiveness of chemotherapy or targeted therapy in breast cancer treatment.•SGLT2 inhibitors can overcome chemo-resistance and improve outcomes for challenging breast cancer. |
|---|---|
| AbstractList | The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the context of BC. Preclinical studies have demonstrated that various SGLT2 inhibitors, such as canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, can inhibit the proliferation of BC cells, induce apoptosis, and modulate key cellular signaling pathways. These mechanisms include the activation of AMP-activated protein kinase (AMPK), suppression of mammalian target of rapamycin (mTOR) signaling, and regulation of lipid metabolism and inflammatory mediators. The combination of SGLT2 inhibitors with conventional treatments, including chemotherapy and radiotherapy, as well as targeted therapies like phosphoinositide 3-kinases (PI3K) inhibitors, has shown promising results in enhancing the anti-cancer efficacy and potentially reducing treatment-related toxicities. The identification of specific biomarkers or genetic signatures that predict responsiveness to SGLT2 inhibitor therapy could enable more personalized treatment selection and optimization, particularly for challenging BC subtypes [e, g., triple negative BC (TNBC)]. Ongoing and future clinical trials investigating the use of SGLT2 inhibitors, both as monotherapy and in combination with other agents, will be crucial in elucidating their translational potential and guiding their integration into comprehensive BC care. Overall, SGLT2 inhibitors represent a novel and promising therapeutic approach with the potential to improve clinical outcomes for patients with various subtypes of BC, including the aggressive and chemo-resistant TNBC.The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the context of BC. Preclinical studies have demonstrated that various SGLT2 inhibitors, such as canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, can inhibit the proliferation of BC cells, induce apoptosis, and modulate key cellular signaling pathways. These mechanisms include the activation of AMP-activated protein kinase (AMPK), suppression of mammalian target of rapamycin (mTOR) signaling, and regulation of lipid metabolism and inflammatory mediators. The combination of SGLT2 inhibitors with conventional treatments, including chemotherapy and radiotherapy, as well as targeted therapies like phosphoinositide 3-kinases (PI3K) inhibitors, has shown promising results in enhancing the anti-cancer efficacy and potentially reducing treatment-related toxicities. The identification of specific biomarkers or genetic signatures that predict responsiveness to SGLT2 inhibitor therapy could enable more personalized treatment selection and optimization, particularly for challenging BC subtypes [e, g., triple negative BC (TNBC)]. Ongoing and future clinical trials investigating the use of SGLT2 inhibitors, both as monotherapy and in combination with other agents, will be crucial in elucidating their translational potential and guiding their integration into comprehensive BC care. Overall, SGLT2 inhibitors represent a novel and promising therapeutic approach with the potential to improve clinical outcomes for patients with various subtypes of BC, including the aggressive and chemo-resistant TNBC. The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the context of BC. Preclinical studies have demonstrated that various SGLT2 inhibitors, such as canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, can inhibit the proliferation of BC cells, induce apoptosis, and modulate key cellular signaling pathways. These mechanisms include the activation of AMP-activated protein kinase (AMPK), suppression of mammalian target of rapamycin (mTOR) signaling, and regulation of lipid metabolism and inflammatory mediators. The combination of SGLT2 inhibitors with conventional treatments, including chemotherapy and radiotherapy, as well as targeted therapies like phosphoinositide 3-kinases (PI3K) inhibitors, has shown promising results in enhancing the anti-cancer efficacy and potentially reducing treatment-related toxicities. The identification of specific biomarkers or genetic signatures that predict responsiveness to SGLT2 inhibitor therapy could enable more personalized treatment selection and optimization, particularly for challenging BC subtypes [e, g., triple negative BC (TNBC)]. Ongoing and future clinical trials investigating the use of SGLT2 inhibitors, both as monotherapy and in combination with other agents, will be crucial in elucidating their translational potential and guiding their integration into comprehensive BC care. Overall, SGLT2 inhibitors represent a novel and promising therapeutic approach with the potential to improve clinical outcomes for patients with various subtypes of BC, including the aggressive and chemo-resistant TNBC. [Display omitted] •SGLT2 inhibitors have shown anti-cancer properties in breast cancer treatment.•Specific SGLT2 inhibitors have demonstrated the ability to inhibit breast cancer cell proliferation.•SGLT2 inhibitors have been found to induce apoptosis in breast cancer cells, potentially contributing to tumor reduction.•These inhibitors have shown a potential to enhance the effectiveness of chemotherapy or targeted therapy in breast cancer treatment.•SGLT2 inhibitors can overcome chemo-resistance and improve outcomes for challenging breast cancer. The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies targeting shared metabolic pathways. This review focuses on the emerging evidence surrounding the potential anti-cancer effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors in the context of BC. Preclinical studies have demonstrated that various SGLT2 inhibitors, such as canagliflozin, dapagliflozin, ipragliflozin, and empagliflozin, can inhibit the proliferation of BC cells, induce apoptosis, and modulate key cellular signaling pathways. These mechanisms include the activation of AMP-activated protein kinase (AMPK), suppression of mammalian target of rapamycin (mTOR) signaling, and regulation of lipid metabolism and inflammatory mediators. The combination of SGLT2 inhibitors with conventional treatments, including chemotherapy and radiotherapy, as well as targeted therapies like phosphoinositide 3-kinases (PI3K) inhibitors, has shown promising results in enhancing the anti-cancer efficacy and potentially reducing treatment-related toxicities. The identification of specific biomarkers or genetic signatures that predict responsiveness to SGLT2 inhibitor therapy could enable more personalized treatment selection and optimization, particularly for challenging BC subtypes [e, g., triple negative BC (TNBC)]. Ongoing and future clinical trials investigating the use of SGLT2 inhibitors, both as monotherapy and in combination with other agents, will be crucial in elucidating their translational potential and guiding their integration into comprehensive BC care. Overall, SGLT2 inhibitors represent a novel and promising therapeutic approach with the potential to improve clinical outcomes for patients with various subtypes of BC, including the aggressive and chemo-resistant TNBC. |
| ArticleNumber | 176803 |
| Author | Tajbakhsh, Amir Naeimzadeh, Yasaman Fallahi, Jafar Nemati, Mahnaz |
| Author_xml | – sequence: 1 givenname: Yasaman orcidid: 0000-0003-3937-1426 surname: Naeimzadeh fullname: Naeimzadeh, Yasaman organization: Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, 7133654361, Iran – sequence: 2 givenname: Amir orcidid: 0000-0002-2311-6554 surname: Tajbakhsh fullname: Tajbakhsh, Amir email: Tajbakhsh.amir921@gmail.com organization: Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran – sequence: 3 givenname: Mahnaz surname: Nemati fullname: Nemati, Mahnaz organization: Amir Oncology Hospital, Shiraz University of Medical Sciences, Shiraz, Iran – sequence: 4 givenname: Jafar surname: Fallahi fullname: Fallahi, Jafar email: jafarf80@gmail.com organization: Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, 7133654361, Iran |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38950839$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkU9vEzEUxC1URNPCN0DIRy4b_GedXXNAQlUpSJE4UM7WW_stcbSxF9sp8O1xtCkHDnCyR-83c5i5IhchBiTkJWdrzvjmzX6N-3kHaS2YaNe82_RMPiEr3ne6YR0XF2TFGG8bobW-JFc57xljSgv1jFzKXivWS70iP25_zlNMPnyjZYcUQvGNhWAx0TkWrBImGkf65W57L6gPOz_4ElOuXzokhFzoGS9VlUN1nE5zwsZOPnhb7RAc_SNyOTqP-Tl5OsKU8cX5vSZfP9ze33xstp_vPt283zZWbkRpuBNuGIVEgU4JELznwKQDLloJbuSq65xybQW4HlBJx5lSigk-CIDN2Mpr8nrJnVP8fsRczMFni9MEAeMxG8m6thNKd6qir87ocTigM3PyB0i_zGNZFXi7ADbFnBOOxvoCxcdQEvjJcGZOy5i9WZYxp2XMskw1t3-ZH_P_Y3u32LCW9OAxmWw91sKdT2iLcdH_O-A3od-qXA |
| CitedBy_id | crossref_primary_10_1186_s43556_024_00204_z crossref_primary_10_1186_s12885_025_14304_8 crossref_primary_10_1016_j_semcancer_2025_07_008 crossref_primary_10_2147_DDDT_S485755 crossref_primary_10_1186_s12885_025_14453_w crossref_primary_10_3390_ph18050681 crossref_primary_10_1016_j_phrs_2025_107811 |
| Cites_doi | 10.1016/j.phrs.2016.07.001 10.1681/ASN.2010030246 10.1016/j.biopha.2020.110708 10.14797/mdcvj.1120 10.1007/s40265-018-0878-6 10.1111/dom.12090 10.1507/endocrj.EJ19-0428 10.1371/journal.pone.0049513 10.1038/ki.2010.511 10.1016/j.molmet.2016.08.014 10.2174/187152608784746501 10.1016/j.neo.2021.02.003 10.1152/physiol.00021.2017 10.3390/cancers14235811 10.1016/j.redox.2021.102006 10.3390/cancers16081538 10.3390/cancers12010154 10.3389/fimmu.2023.1163288 10.3390/cancers13164184 10.1016/j.clinthera.2014.12.013 10.1038/s42003-022-03422-9 10.3390/life13112213 10.1016/j.biopha.2022.113675 10.3390/cancers12082252 10.1093/eurheartj/ehab724.2846 10.1016/j.biopha.2020.110821 10.1016/j.ajpath.2013.07.035 10.2741/s30 10.1080/00325481.2018.1394152 10.2337/dcS15-3006 10.1007/s12253-011-9466-8 10.1210/er.2011-1015 10.1096/fasebj.2019.33.1_supplement.647.48 10.3390/cells9061380 10.3390/biomedicines11071867 10.1016/S0140-6736(05)72477-6 10.1016/j.ejphar.2023.175565 10.1007/s40264-023-01373-6 10.1007/s11060-018-2823-7 10.1007/s40265-014-0204-x 10.1016/j.stemcr.2019.02.011 10.1016/j.ejps.2016.08.025 10.1038/s41467-020-15219-7 10.1016/j.compbiomed.2023.107552 10.1007/s40265-014-0230-8 10.1177/1479164114561992 10.1111/dom.12572 10.1038/s41388-020-1202-y 10.1038/s41420-020-0260-9 10.1002/ptr.6421 10.1056/NEJMoa021423 10.1007/s13300-015-0128-9 10.1016/j.mce.2021.111213 10.1210/er.2010-0030 10.1007/s11892-016-0789-4 10.1016/j.critrevonc.2023.104249 10.3390/cancers15174250 10.18632/oncotarget.17853 10.1158/0008-5472.CAN-09-2141 10.1158/1055-9965.EPI-17-0439 10.1016/j.ccell.2020.05.022 10.1038/nrc3829 10.1002/ijc.32310 10.1186/s12978-022-01374-1 10.1007/s00125-018-4664-5 10.1007/s12672-023-00719-x 10.1016/j.lfs.2023.121781 10.1038/nrm2391 10.32604/or.2024.048988 10.1016/j.stemcr.2022.04.007 10.2337/db10-1328 10.1038/bjc.2016.37 10.1111/ans.12877 10.1158/0008-5472.CAN-18-3959 10.1002/ijc.31193 10.1007/s00125-017-4229-z 10.1681/ASN.2010080888 10.4103/jrms.JRMS_242_19 10.1016/j.jconrel.2017.09.003 10.2337/dc13-2955 10.3389/fphar.2021.752440 10.1038/s41419-023-05930-w 10.1016/j.ejphar.2024.176328 10.1007/s00204-020-02951-8 10.1021/acsptsci.0c00144 10.3390/ijms21207802 10.1080/2314808X.2022.2145734 10.1677/ERC-09-0087 10.4103/2229-516X.165363 10.3390/cancers14030574 10.1073/pnas.1511698112 10.1016/j.metabol.2018.10.013 10.1016/bs.acr.2018.05.001 10.1016/j.diabres.2009.10.007 10.1016/j.celrep.2020.108487 10.1038/s41419-017-0140-2 10.2147/TCRM.S137068 10.1007/s10549-015-3583-0 10.1007/s00210-011-0713-z 10.1056/NEJMoa1504720 10.2337/dc14-0315 10.3390/ijms22031444 10.1186/s40170-020-00222-9 10.1007/s40262-020-00875-1 10.1007/s40265-014-0229-1 10.1023/A:1005831013718 10.4093/dmj.2019.0177 10.4093/dmj.2014.38.5.330 10.1111/dom.12124 10.1210/endrev/bnad005 10.2147/DDDT.S50773 |
| ContentType | Journal Article |
| Copyright | 2024 Elsevier B.V. Copyright © 2024 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2024 Elsevier B.V. – notice: Copyright © 2024 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ejphar.2024.176803 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-0712 |
| ExternalDocumentID | 38950839 10_1016_j_ejphar_2024_176803 S0014299924004916 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M -~X .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5RE 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAXLA AAXUO ABCQJ ABFNM ABFRF ABJNI ABMAC ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGWIK AGYEJ AIEXJ AIKHN AITUG AJOXV AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W K-O KOM L7B MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SSN SSP T5K TEORI ~G- .55 .GJ 29G 3O- 53G 5VS 9DU AAQXK AATTM AAXKI AAYWO AAYXX ABWVN ABXDB ACLOT ACRPL ACVFH ADCNI ADMUD ADNMO AEIPS AEUPX AFJKZ AFPUW AGHFR AGQPQ AHHHB AIGII AIIUN AKBMS AKYEP ANKPU APXCP ASPBG AVWKF AZFZN CITATION EFKBS EFLBG EJD FEDTE FGOYB G-2 HMQ HMT HVGLF HZ~ M2V M34 M41 R2- SNS SPT SSZ WUQ X7M ZGI ~HD AGCQF AGRNS BNPGV CGR CUY CVF ECM EIF NPM SSH 7X8 |
| ID | FETCH-LOGICAL-c362t-1d2dbf23e2ed52a2181a03da1243adf1577d5d423e19be53d10555021b2aa6f43 |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001266292000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0014-2999 1879-0712 |
| IngestDate | Sun Nov 09 12:58:52 EST 2025 Mon Jul 21 05:33:08 EDT 2025 Tue Nov 18 22:46:15 EST 2025 Sat Nov 29 02:49:54 EST 2025 Sat Jul 27 15:41:14 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Breast neoplasms Gene mutations Precision medicine Antineoplastic agents SGLT2 inhibitor Diabetes mellitus |
| Language | English |
| License | Copyright © 2024 Elsevier B.V. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c362t-1d2dbf23e2ed52a2181a03da1243adf1577d5d423e19be53d10555021b2aa6f43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-2311-6554 0000-0003-3937-1426 |
| PMID | 38950839 |
| PQID | 3074725975 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3074725975 pubmed_primary_38950839 crossref_citationtrail_10_1016_j_ejphar_2024_176803 crossref_primary_10_1016_j_ejphar_2024_176803 elsevier_sciencedirect_doi_10_1016_j_ejphar_2024_176803 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-05 |
| PublicationDateYYYYMMDD | 2024-09-05 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | European journal of pharmacology |
| PublicationTitleAlternate | Eur J Pharmacol |
| PublicationYear | 2024 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Del Giudice (bib35) 1998; 47 Gallo (bib50) 2015; 12 Tilekar (bib119) 2020; 1874 Barbosa, Martel (bib11) 2020; 12 Dutka (bib38) 2022; 14 Wang (bib127) 2024; 47 Bocian-Jastrzębska (bib17) 2023; 15 Eliaa (bib41) 2020; 3 Argilés (bib8) 2014; 14 Shahruzaman (bib109) 2019; 19 Gui (bib54) 2017; 8 Tahara (bib117) 2012; 385 Zakikhani (bib139) 2012; 7 Yuan (bib138) 2020; 38 Anker, Butler (bib7) 2018 Shao (bib110) 2018; 27 Batra (bib14) 2023; 10 Barańska (bib10) 2022; 14 Sabaa (bib105) 2022; 155 Novosyadlyy (bib91) 2010; 70 Kennedy (bib65) 2020; 39 López-Suárez (bib76) 2019; 92 Scheen (bib108) 2016; 16 Alblowy (bib3) 2023; 166 Carberry (bib19) 2018; 9 DeFronzo (bib34) 2015; 1 (bib47) 2014 Scafoglio (bib107) 2015; 112 Wright (bib131) 2017; 32 Villani (bib126) 2016; 5 Ryu (bib104) 2014; 38 Suh, Kim (bib115) 2019; 43 Fediuk (bib44) 2020; 59 Chidambaram (bib25) 2022; 17 Tsilidis (bib120) 2015; 350 Ziegler (bib144) 2019; 12 Perelman (bib96) 2024; 10 Dalamaga (bib33) 2012; 33 Vallon (bib122) 2011; 22 Eketunde (bib39) 2020; 12 Fioretto (bib46) 2016; 39 Luis (bib78) 2021; 43 Wu (bib132) 2023; 14 Malhotra (bib81) 2015; 5 Poole, Dungo (bib99) 2014; 74 (bib48) 2014 Yale (bib135) 2013; 15 Jurczak (bib60) 2011; 60 Crunkhorn (bib32) 2019; 18 Cefalu (bib21) 2015; 38 Padhi (bib93) 2020; 131 Zhou (bib141) 2015; 85 Karim (bib64) 2024; 32 Chen (bib23) 2017; 60 Nalla, Khairnar (bib88) 2023; 943 Colakoglu (bib28) 2017; 118 Guilherme (bib55) 2008; 9 Garg (bib52) 2014; 16 Pham, Park (bib97) 2021; 22 Ptaszynska (bib102) 2015; 6 Mazzieri (bib85) 2023; 14 Chilton (bib26) 2015; 17 Madaan (bib80) 2016; 93 Tasnim (bib118) 2022; 19 Basak (bib13) 2023; 11 (bib49) 2014 Alblowy (bib4) 2023 Longaray (bib75) 2024; 966 Liang (bib72) 2020; 10 Maurea (bib84) 2021; 42 (bib6) 2023 Suba (bib114) 2012; 18 Cleary (bib27) 2009; 1 Zinman (bib145) 2015; 373 Chen (bib24) 2023; 14 Filippas-Ntekouan (bib45) 2018; 130 Markham, Elkinson (bib83) 2014; 74 Srivastava, Goodwin (bib112) 2020; 9 Coller (bib29) 2014; 184 Uzma (bib121) 2020; 10 Yang (bib136) 2016; 113 Erber (bib42) 2019; 79 Lero, Shaw (bib71) 2021; 527 Isaji (bib58) 2011; 79 Komatsu (bib67) 2020; 67 Calle (bib18) 2003; 348 Connor, Broome (bib31) 2018; 139 Pliszka, Szablewski (bib98) 2021; 13 Kansara (bib62) 2022; 18 Ohkuma (bib92) 2018; 61 García-Jiménez (bib51) 2016; 114 Bardaweel (bib12) 2022; 25 Novartis Pharmaceuticals (bib113) Goto (bib53) 2020; 146 Varghese (bib123) 2020; 12 Vella (bib124) 2023; 44 Akingbesote (bib2) 2022; 5 Vigneri (bib125) 2009; 16 Leprivier, Rotblat (bib70) 2020; 6 Zhu, Qu (bib143) 2022; 13 Chang (bib22) 2021; 95 Ly (bib79) 2011; 22 Nauck (bib89) 2014; 11 Henry (bib56) 2015; 38 Karim (bib63) 2024; 32 Alhajahjeh (bib5) 2024; 16 Markham (bib82) 2018; 78 Sun (bib116) 2024; 15 Liang (bib73) 2023 Memorial Sloan Kettering Cancer Center (bib101) Zhou (bib142) 2020; 132 Devineni (bib37) 2015; 37 Bharti (bib16) 2023 Begum (bib15) 2023; 13 Kuang (bib68) 2017; 23 Cebioglu (bib20) 2008; 8 Yu (bib137) 2019; 98 Kepe (bib66) 2018; 138 Liu (bib74) 2022; 12 Abudawood (bib1) 2019; 24 Samare-Najaf (bib106) 2024; 194 Jiang (bib59) 2015; 153 Kaji (bib61) 2018; 142 Shaw (bib111) 2010; 87 Poole, Prossler (bib100) 2014; 74 Ware (bib129) 2019; 33 Wong (bib130) 2017; 264 Moradi‐Marjaneh (bib86) 2019; 33 Xiong (bib134) 2023 Faillie (bib43) 2017; 118 Larkin (bib69) 2000; 355 Commander (bib30) 2020; 11 (bib57) 2013 Luis (bib77) 2021; 43 Derosa, Maffioli (bib36) 2018 Papadopoli (bib94) 2021; 23 Xie (bib133) 2022; 13 Armaghani, Han (bib9) 2020 Nakagawa (bib87) 2020; 8 Park (bib95) 2011; 32 Quagliariello (bib103) 2020; 21 Zhao (bib140) 2020; 33 Erber (10.1016/j.ejphar.2024.176803_bib42) 2019; 79 Barańska (10.1016/j.ejphar.2024.176803_bib10) 2022; 14 Villani (10.1016/j.ejphar.2024.176803_bib126) 2016; 5 Wright (10.1016/j.ejphar.2024.176803_bib131) 2017; 32 Abudawood (10.1016/j.ejphar.2024.176803_bib1) 2019; 24 Longaray (10.1016/j.ejphar.2024.176803_bib75) 2024; 966 Jiang (10.1016/j.ejphar.2024.176803_bib59) 2015; 153 Cleary (10.1016/j.ejphar.2024.176803_bib27) 2009; 1 Eketunde (10.1016/j.ejphar.2024.176803_bib39) 2020; 12 Gallo (10.1016/j.ejphar.2024.176803_bib50) 2015; 12 Bharti (10.1016/j.ejphar.2024.176803_bib16) 2023 Basak (10.1016/j.ejphar.2024.176803_bib13) 2023; 11 Wong (10.1016/j.ejphar.2024.176803_bib130) 2017; 264 Argilés (10.1016/j.ejphar.2024.176803_bib8) 2014; 14 Tahara (10.1016/j.ejphar.2024.176803_bib117) 2012; 385 Alhajahjeh (10.1016/j.ejphar.2024.176803_bib5) 2024; 16 Vallon (10.1016/j.ejphar.2024.176803_bib122) 2011; 22 Madaan (10.1016/j.ejphar.2024.176803_bib80) 2016; 93 Pham (10.1016/j.ejphar.2024.176803_bib97) 2021; 22 Calle (10.1016/j.ejphar.2024.176803_bib18) 2003; 348 Carberry (10.1016/j.ejphar.2024.176803_bib19) 2018; 9 Park (10.1016/j.ejphar.2024.176803_bib95) 2011; 32 Perelman (10.1016/j.ejphar.2024.176803_bib96) 2024; 10 Gui (10.1016/j.ejphar.2024.176803_bib54) 2017; 8 Wu (10.1016/j.ejphar.2024.176803_bib132) 2023; 14 Chang (10.1016/j.ejphar.2024.176803_bib22) 2021; 95 Begum (10.1016/j.ejphar.2024.176803_bib15) 2023; 13 Dalamaga (10.1016/j.ejphar.2024.176803_bib33) 2012; 33 Luis (10.1016/j.ejphar.2024.176803_bib78) 2021; 43 Yang (10.1016/j.ejphar.2024.176803_bib136) 2016; 113 Zhu (10.1016/j.ejphar.2024.176803_bib143) 2022; 13 Nauck (10.1016/j.ejphar.2024.176803_bib89) 2014; 11 (10.1016/j.ejphar.2024.176803_bib48) 2014 Batra (10.1016/j.ejphar.2024.176803_bib14) 2023; 10 Anker (10.1016/j.ejphar.2024.176803_bib7) 2018 Commander (10.1016/j.ejphar.2024.176803_bib30) 2020; 11 Nalla (10.1016/j.ejphar.2024.176803_bib88) 2023; 943 Karim (10.1016/j.ejphar.2024.176803_bib63) 2024; 32 Quagliariello (10.1016/j.ejphar.2024.176803_bib103) 2020; 21 Xie (10.1016/j.ejphar.2024.176803_bib133) 2022; 13 Eliaa (10.1016/j.ejphar.2024.176803_bib41) 2020; 3 Memorial Sloan Kettering Cancer Center (10.1016/j.ejphar.2024.176803_bib101) Shaw (10.1016/j.ejphar.2024.176803_bib111) 2010; 87 DeFronzo (10.1016/j.ejphar.2024.176803_bib34) 2015; 1 Ryu (10.1016/j.ejphar.2024.176803_bib104) 2014; 38 Bardaweel (10.1016/j.ejphar.2024.176803_bib12) 2022; 25 Ptaszynska (10.1016/j.ejphar.2024.176803_bib102) 2015; 6 Del Giudice (10.1016/j.ejphar.2024.176803_bib35) 1998; 47 (10.1016/j.ejphar.2024.176803_bib57) 2013 Maurea (10.1016/j.ejphar.2024.176803_bib84) 2021; 42 Vigneri (10.1016/j.ejphar.2024.176803_bib125) 2009; 16 Alblowy (10.1016/j.ejphar.2024.176803_bib3) 2023; 166 (10.1016/j.ejphar.2024.176803_bib47) 2014 Ohkuma (10.1016/j.ejphar.2024.176803_bib92) 2018; 61 Moradi‐Marjaneh (10.1016/j.ejphar.2024.176803_bib86) 2019; 33 Zhou (10.1016/j.ejphar.2024.176803_bib141) 2015; 85 Derosa (10.1016/j.ejphar.2024.176803_bib36) 2018 Yu (10.1016/j.ejphar.2024.176803_bib137) 2019; 98 Varghese (10.1016/j.ejphar.2024.176803_bib123) 2020; 12 Dutka (10.1016/j.ejphar.2024.176803_bib38) 2022; 14 Kuang (10.1016/j.ejphar.2024.176803_bib68) 2017; 23 Kepe (10.1016/j.ejphar.2024.176803_bib66) 2018; 138 Scafoglio (10.1016/j.ejphar.2024.176803_bib107) 2015; 112 Chidambaram (10.1016/j.ejphar.2024.176803_bib25) 2022; 17 García-Jiménez (10.1016/j.ejphar.2024.176803_bib51) 2016; 114 Novosyadlyy (10.1016/j.ejphar.2024.176803_bib91) 2010; 70 Jurczak (10.1016/j.ejphar.2024.176803_bib60) 2011; 60 Wang (10.1016/j.ejphar.2024.176803_bib127) 2024; 47 Kaji (10.1016/j.ejphar.2024.176803_bib61) 2018; 142 Bocian-Jastrzębska (10.1016/j.ejphar.2024.176803_bib17) 2023; 15 Isaji (10.1016/j.ejphar.2024.176803_bib58) 2011; 79 Leprivier (10.1016/j.ejphar.2024.176803_bib70) 2020; 6 Kennedy (10.1016/j.ejphar.2024.176803_bib65) 2020; 39 Samare-Najaf (10.1016/j.ejphar.2024.176803_bib106) 2024; 194 Garg (10.1016/j.ejphar.2024.176803_bib52) 2014; 16 Chilton (10.1016/j.ejphar.2024.176803_bib26) 2015; 17 Suba (10.1016/j.ejphar.2024.176803_bib114) 2012; 18 (10.1016/j.ejphar.2024.176803_bib49) 2014 Zinman (10.1016/j.ejphar.2024.176803_bib145) 2015; 373 Fioretto (10.1016/j.ejphar.2024.176803_bib46) 2016; 39 Zhao (10.1016/j.ejphar.2024.176803_bib140) 2020; 33 Uzma (10.1016/j.ejphar.2024.176803_bib121) 2020; 10 Shao (10.1016/j.ejphar.2024.176803_bib110) 2018; 27 Xiong (10.1016/j.ejphar.2024.176803_bib134) 2023 Chen (10.1016/j.ejphar.2024.176803_bib24) 2023; 14 Liang (10.1016/j.ejphar.2024.176803_bib73) 2023 Barbosa (10.1016/j.ejphar.2024.176803_bib11) 2020; 12 Henry (10.1016/j.ejphar.2024.176803_bib56) 2015; 38 Tilekar (10.1016/j.ejphar.2024.176803_bib119) 2020; 1874 Fediuk (10.1016/j.ejphar.2024.176803_bib44) 2020; 59 Nakagawa (10.1016/j.ejphar.2024.176803_bib87) 2020; 8 Kansara (10.1016/j.ejphar.2024.176803_bib62) 2022; 18 López-Suárez (10.1016/j.ejphar.2024.176803_bib76) 2019; 92 Vella (10.1016/j.ejphar.2024.176803_bib124) 2023; 44 Scheen (10.1016/j.ejphar.2024.176803_bib108) 2016; 16 Cefalu (10.1016/j.ejphar.2024.176803_bib21) 2015; 38 Papadopoli (10.1016/j.ejphar.2024.176803_bib94) 2021; 23 Karim (10.1016/j.ejphar.2024.176803_bib64) 2024; 32 Yuan (10.1016/j.ejphar.2024.176803_bib138) 2020; 38 Goto (10.1016/j.ejphar.2024.176803_bib53) 2020; 146 Guilherme (10.1016/j.ejphar.2024.176803_bib55) 2008; 9 Pliszka (10.1016/j.ejphar.2024.176803_bib98) 2021; 13 Malhotra (10.1016/j.ejphar.2024.176803_bib81) 2015; 5 Filippas-Ntekouan (10.1016/j.ejphar.2024.176803_bib45) 2018; 130 Tsilidis (10.1016/j.ejphar.2024.176803_bib120) 2015; 350 Novartis Pharmaceuticals (10.1016/j.ejphar.2024.176803_bib113) Mazzieri (10.1016/j.ejphar.2024.176803_bib85) 2023; 14 Padhi (10.1016/j.ejphar.2024.176803_bib93) 2020; 131 Shahruzaman (10.1016/j.ejphar.2024.176803_bib109) 2019; 19 Markham (10.1016/j.ejphar.2024.176803_bib83) 2014; 74 Komatsu (10.1016/j.ejphar.2024.176803_bib67) 2020; 67 Connor (10.1016/j.ejphar.2024.176803_bib31) 2018; 139 Suh (10.1016/j.ejphar.2024.176803_bib115) 2019; 43 Yale (10.1016/j.ejphar.2024.176803_bib135) 2013; 15 Cebioglu (10.1016/j.ejphar.2024.176803_bib20) 2008; 8 Markham (10.1016/j.ejphar.2024.176803_bib82) 2018; 78 Larkin (10.1016/j.ejphar.2024.176803_bib69) 2000; 355 Srivastava (10.1016/j.ejphar.2024.176803_bib112) 2020; 9 Liang (10.1016/j.ejphar.2024.176803_bib72) 2020; 10 Zhou (10.1016/j.ejphar.2024.176803_bib142) 2020; 132 Lero (10.1016/j.ejphar.2024.176803_bib71) 2021; 527 Akingbesote (10.1016/j.ejphar.2024.176803_bib2) 2022; 5 Tasnim (10.1016/j.ejphar.2024.176803_bib118) 2022; 19 Crunkhorn (10.1016/j.ejphar.2024.176803_bib32) 2019; 18 Zakikhani (10.1016/j.ejphar.2024.176803_bib139) 2012; 7 Poole (10.1016/j.ejphar.2024.176803_bib99) 2014; 74 Poole (10.1016/j.ejphar.2024.176803_bib100) 2014; 74 Sun (10.1016/j.ejphar.2024.176803_bib116) 2024; 15 Coller (10.1016/j.ejphar.2024.176803_bib29) 2014; 184 Liu (10.1016/j.ejphar.2024.176803_bib74) 2022; 12 Faillie (10.1016/j.ejphar.2024.176803_bib43) 2017; 118 Ware (10.1016/j.ejphar.2024.176803_bib129) 2019; 33 Alblowy (10.1016/j.ejphar.2024.176803_bib4) 2023 Luis (10.1016/j.ejphar.2024.176803_bib77) 2021; 43 Armaghani (10.1016/j.ejphar.2024.176803_bib9) 2020 Chen (10.1016/j.ejphar.2024.176803_bib23) 2017; 60 Ziegler (10.1016/j.ejphar.2024.176803_bib144) 2019; 12 Devineni (10.1016/j.ejphar.2024.176803_bib37) 2015; 37 Ly (10.1016/j.ejphar.2024.176803_bib79) 2011; 22 Colakoglu (10.1016/j.ejphar.2024.176803_bib28) 2017; 118 Sabaa (10.1016/j.ejphar.2024.176803_bib105) 2022; 155 (10.1016/j.ejphar.2024.176803_bib6) 2023 |
| References_xml | – volume: 13 year: 2022 ident: bib133 article-title: Emerging roles of sodium glucose cotransporter 2 (SGLT-2) inhibitors in diabetic cardiovascular diseases: focusing on immunity, inflammation and metabolism publication-title: Front. Pharmacol. – volume: 12 start-page: 154 year: 2020 ident: bib11 article-title: Targeting glucose transporters for breast cancer therapy: the effect of natural and synthetic compounds publication-title: Cancers – volume: 95 start-page: 659 year: 2021 end-page: 671 ident: bib22 article-title: Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients publication-title: Arch. Toxicol. – volume: 11 start-page: 1867 year: 2023 ident: bib13 article-title: SGLT2 inhibitors as potential anticancer agents publication-title: Biomedicines – volume: 113 start-page: E4966 year: 2016 end-page: E4975 ident: bib136 publication-title: Peroxidation of Polyunsaturated Fatty Acids by Lipoxygenases Drives Ferroptosis – volume: 15 start-page: 4250 year: 2023 ident: bib17 article-title: Role of leptin and adiponectin in carcinogenesis publication-title: Cancers – volume: 12 year: 2022 ident: bib74 article-title: Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis publication-title: Front. Pharmacol. – volume: 79 start-page: S14 year: 2011 end-page: S19 ident: bib58 article-title: SGLT2 inhibitors: molecular design and potential differences in effect publication-title: Kidney Int. – volume: 33 year: 2019 ident: bib129 article-title: The effect of sodium glucose transporter 2 inhibitors on proliferation and growth factor signaling pathways in triple negative breast cancer publication-title: Faseb. J. – volume: 74 start-page: 945 year: 2014 end-page: 950 ident: bib83 article-title: Luseogliflozin: first global approval publication-title: Drugs – volume: 13 start-page: 2213 year: 2023 ident: bib15 article-title: Adiponectin: a promising target for the treatment of diabetes and its complications publication-title: Life – volume: 114 start-page: 716 year: 2016 end-page: 722 ident: bib51 article-title: From obesity to diabetes and cancer: epidemiological links and role of therapies publication-title: Br. J. Cancer – volume: 67 start-page: 99 year: 2020 end-page: 106 ident: bib67 article-title: SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation publication-title: Endocr. J. – ident: bib101 article-title: Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer – volume: 16 start-page: 1103 year: 2009 end-page: 1123 ident: bib125 article-title: Diabetes and cancer publication-title: Endocr. Relat. Cancer – volume: 47 start-page: 125 year: 2024 end-page: 133 ident: bib127 article-title: SGLT2 inhibitor use and risk of breast cancer among adult women with type 2 diabetes publication-title: Drug Saf. – volume: 16 start-page: 1538 year: 2024 ident: bib5 article-title: From diabetes to Oncology: glucagon-like peptide-1 (GLP-1) receptor agonist's dual role in prostate cancer publication-title: Cancers – volume: 10 start-page: 1548 year: 2020 ident: bib72 article-title: SLC25A18 has prognostic value in colorectal cancer and represses Warburg effect and cell proliferation via Wnt signaling publication-title: Am. J. Cancer Res. – volume: 33 year: 2020 ident: bib140 article-title: HCAR1/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications publication-title: Cell Rep. – volume: 27 start-page: 50 year: 2018 end-page: 57 ident: bib110 article-title: Diabetes and overall survival among breast cancer patients in the US military health system publication-title: Cancer Epidemiol. Biomarkers Prev. – volume: 14 start-page: 460 year: 2023 ident: bib24 article-title: Ferroptosis as a potential target for cancer therapy publication-title: Cell Death Dis. – volume: 132 year: 2020 ident: bib142 article-title: Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway publication-title: Biomed. Pharmacother. – volume: 118 start-page: 71 year: 2017 end-page: 81 ident: bib43 article-title: Pharmacological aspects of the safety of gliflozins publication-title: Pharmacol. Res. – start-page: 251 year: 2020 end-page: 258 ident: bib9 article-title: Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data publication-title: Breast Cancer – volume: 348 start-page: 1625 year: 2003 end-page: 1638 ident: bib18 article-title: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults publication-title: N. Engl. J. Med. – volume: 6 start-page: 27 year: 2020 ident: bib70 article-title: How does mTOR sense glucose starvation? AMPK is the usual suspect publication-title: Cell death discovery – volume: 527 year: 2021 ident: bib71 article-title: Diversity of insulin and IGF signaling in breast cancer: implications for therapy publication-title: Mol. Cell. Endocrinol. – year: 2014 ident: bib47 article-title: FDA Approves Invokana to Treat Type 2 Diabetes – volume: 43 year: 2021 ident: bib78 article-title: Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence publication-title: Redox Biol. – volume: 24 year: 2019 ident: bib1 article-title: Diabetes and cancer: a comprehensive review publication-title: J. Res. Med. Sci.: The Official Journal of Isfahan University of Medical Sciences – volume: 74 start-page: 611 year: 2014 end-page: 617 ident: bib99 article-title: Ipragliflozin: first global approval publication-title: Drugs – volume: 85 start-page: 972 year: 2015 end-page: 978 ident: bib141 article-title: Influence of diabetes mellitus on mortality in breast cancer patients publication-title: ANZ J. Surg. – volume: 7 year: 2012 ident: bib139 article-title: Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin publication-title: PLoS One – volume: 92 start-page: 136 year: 2019 end-page: 146 ident: bib76 article-title: Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors publication-title: Metabolism – volume: 130 start-page: 72 year: 2018 end-page: 82 ident: bib45 article-title: SGLT2 inhibitors: are they safe? publication-title: PGM (Postgrad. Med.) – volume: 39 start-page: 3028 year: 2020 end-page: 3040 ident: bib65 article-title: Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer publication-title: Oncogene – volume: 43 year: 2021 ident: bib77 article-title: Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence publication-title: Redox Biol. – volume: 18 start-page: 123 year: 2012 end-page: 133 ident: bib114 article-title: Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis publication-title: Pathol. Oncol. Res. – volume: 47 start-page: 111 year: 1998 end-page: 120 ident: bib35 article-title: Insulin and related factors in premenopausal breast cancer risk publication-title: Breast Cancer Res. Treat. – volume: 355 start-page: 854 year: 2000 ident: bib69 article-title: UK medicines information publication-title: Lancet – volume: 14 year: 2023 ident: bib85 article-title: GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway publication-title: Front. Immunol. – volume: 9 start-page: 125 year: 2018 ident: bib19 article-title: The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer publication-title: Cell Death Dis. – volume: 74 start-page: 939 year: 2014 end-page: 944 ident: bib100 article-title: Tofogliflozin: first global approval publication-title: Drugs – volume: 18 year: 2019 ident: bib32 article-title: Repurposing SGLT2 inhibitors publication-title: Nat. Rev. Drug Discov. – volume: 146 start-page: 712 year: 2020 end-page: 719 ident: bib53 article-title: Diabetes and cancer risk: a Mendelian randomization study publication-title: Int. J. Cancer – volume: 13 year: 2022 ident: bib143 article-title: The relationship between diabetes mellitus and cancers and its underlying mechanisms publication-title: Front. Endocrinol. – start-page: 549 year: 2018 end-page: 551 ident: bib7 article-title: Empagliflozin, Calcium, and SGLT1/2 Receptor Affinity: Another Piece of the Puzzle – year: 2014 ident: bib49 article-title: FDA Approves Farxiga to Treat Type 2 Diabetes. Internet – volume: 93 start-page: 244 year: 2016 end-page: 252 ident: bib80 article-title: Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective publication-title: Eur. J. Pharmaceut. Sci. – volume: 61 start-page: 2140 year: 2018 end-page: 2154 ident: bib92 article-title: Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events publication-title: Diabetologia – volume: 10 start-page: 52 year: 2020 end-page: 57 ident: bib121 article-title: An in-vitro and in silico anticancer study of FDA approved antidiabetic drugs glimepiride and empagliflozin publication-title: Int. J. Pharma Bio Sci. – year: 2023 ident: bib4 article-title: Optimal control strategies for SGLT2 inhibitors as a novel anti-tumor agent and their effect on human breast cancer cells with the effect of time delay and hyperglycemia risk factor publication-title: Comput. Biol. Med. – volume: 32 start-page: 817 year: 2024 end-page: 830 ident: bib64 article-title: A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells publication-title: Oncol. Res. – year: 2023 ident: bib134 article-title: Diabetes and incidence of breast cancer and its molecular subtypes: a systematic review and meta-analysis publication-title: medRxiv, 2023.2005. 2013.23289893 – volume: 118 start-page: 394 year: 2017 end-page: 398 ident: bib28 article-title: Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer publication-title: Bratisl. Lek. Listy – volume: 184 start-page: 4 year: 2014 end-page: 17 ident: bib29 article-title: Is cancer a metabolic disease? publication-title: Am. J. Pathol. – volume: 373 start-page: 2117 year: 2015 end-page: 2128 ident: bib145 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N. Engl. J. Med. – volume: 142 start-page: 1712 year: 2018 end-page: 1722 ident: bib61 article-title: Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake publication-title: Int. J. Cancer – volume: 1 start-page: 329 year: 2009 end-page: 357 ident: bib27 article-title: Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention publication-title: Front. Biosci. – volume: 16 start-page: 97 year: 2014 end-page: 110 ident: bib52 article-title: Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes publication-title: Obes. Metabol. – volume: 112 start-page: E4111 year: 2015 end-page: E4119 ident: bib107 article-title: Functional expression of sodium-glucose transporters in cancer publication-title: Proc. Natl. Acad. Sci. USA – volume: 17 start-page: 1411 year: 2022 end-page: 1427 ident: bib25 article-title: Subventricular zone adult mouse neural stem cells require insulin receptor for self-renewal publication-title: Stem Cell Rep. – volume: 98 year: 2019 ident: bib137 article-title: Association of serum adiponectin with breast cancer: a meta-analysis of 27 case-control studies publication-title: Medicine – volume: 37 start-page: 610 year: 2015 end-page: 628. e614 ident: bib37 article-title: Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor publication-title: Clin. Therapeut. – volume: 13 start-page: 4184 year: 2021 ident: bib98 article-title: Glucose transporters as a target for anticancer therapy publication-title: Cancers – volume: 131 year: 2020 ident: bib93 article-title: Type II diabetes mellitus: a review on recent drug based therapeutics publication-title: Biomed. Pharmacother. – volume: 5 start-page: 1048 year: 2016 end-page: 1056 ident: bib126 article-title: The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration publication-title: Mol. Metabol. – volume: 15 year: 2024 ident: bib116 article-title: Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential publication-title: Front. Pharmacol. – volume: 18 start-page: 62 year: 2022 ident: bib62 article-title: SGLT2 inhibitors in patients with chronic kidney disease and heart disease: a literature review publication-title: Methodist DeBakey Cardiovascular Journal – volume: 5 start-page: 478 year: 2022 ident: bib2 article-title: A precision medicine approach to metabolic therapy for breast cancer in mice publication-title: Commun. Biol. – volume: 11 start-page: 1335 year: 2014 end-page: 1380 ident: bib89 article-title: Update on developments with SGLT2 inhibitors in the management of type 2 diabetes publication-title: Drug Des. Dev. Ther. – volume: 12 start-page: 816 year: 2019 end-page: 830 ident: bib144 article-title: Insulin-like growth factor II: an essential adult stem cell niche constituent in brain and intestine publication-title: Stem Cell Rep. – volume: 39 start-page: S165 year: 2016 end-page: S171 ident: bib46 article-title: SGLT2 inhibitors and the diabetic kidney publication-title: Diabetes Care – volume: 78 start-page: 513 year: 2018 end-page: 519 ident: bib82 article-title: Ertugliflozin: first global approval publication-title: Drugs – volume: 60 start-page: 890 year: 2011 end-page: 898 ident: bib60 article-title: SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function publication-title: Diabetes – volume: 43 start-page: 733 year: 2019 end-page: 743 ident: bib115 article-title: Diabetes and cancer: cancer should be screened in routine diabetes assessment publication-title: Diabetes & metabolism journal – volume: 8 start-page: 1 year: 2020 end-page: 12 ident: bib87 article-title: Fructose contributes to the Warburg effect for cancer growth publication-title: Cancer Metabol. – volume: 38 start-page: 412 year: 2015 end-page: 419 ident: bib56 article-title: Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study publication-title: Diabetes Care – volume: 9 start-page: 367 year: 2008 end-page: 377 ident: bib55 article-title: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes publication-title: Nat. Rev. Mol. Cell Biol. – year: 2023 ident: bib73 article-title: Glycosylation in breast cancer progression and mammary development: molecular connections and malignant transformations publication-title: Life Sci. – volume: 153 start-page: 519 year: 2015 end-page: 529 ident: bib59 article-title: Exogenous normal mammary epithelial mitochondria suppress glycolytic metabolism and glucose uptake of human breast cancer cells publication-title: Breast Cancer Res. Treat. – volume: 14 start-page: 574 year: 2022 ident: bib10 article-title: Oral contraceptive use and breast cancer risk according to molecular subtypes status: a systematic review and meta-analysis of case-control studies publication-title: Cancers – volume: 25 start-page: 253 year: 2022 end-page: 265 ident: bib12 article-title: Exploring the role of sodium-glucose cotransporter as a new target for cancer therapy publication-title: J. Pharm. Pharmaceut. Sci. – volume: 23 start-page: 391 year: 2021 end-page: 399 ident: bib94 article-title: Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin publication-title: Neoplasia – volume: 79 start-page: 4855 year: 2019 end-page: 4868 ident: bib42 article-title: Dual inhibition of GLUT1 and the ATR/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells publication-title: Cancer Res. – year: 2014 ident: bib48 article-title: FDA Approves Jardiance to Treat Type 2 Diabetes – volume: 5 start-page: 161 year: 2015 ident: bib81 article-title: Sodium glucose co-transporter inhibitors–A new class of old drugs publication-title: International Journal of Applied and Basic Medical Research – year: 2023 ident: bib6 article-title: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer – volume: 264 start-page: 247 year: 2017 end-page: 275 ident: bib130 article-title: Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment publication-title: J. Contr. Release – start-page: 1637 year: 2018 end-page: 1640 ident: bib36 article-title: Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes publication-title: Therapeut. Clin. Risk Manag. – volume: 6 start-page: 357 year: 2015 end-page: 375 ident: bib102 article-title: Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’ publication-title: Diabetes Therapy – volume: 12 start-page: 78 year: 2015 end-page: 89 ident: bib50 article-title: Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences publication-title: Diabetes Vasc. Dis. Res. – volume: 59 start-page: 949 year: 2020 end-page: 965 ident: bib44 article-title: Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor publication-title: Clin. Pharmacokinet. – ident: bib113 article-title: Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4) – volume: 32 start-page: 550 year: 2011 end-page: 570 ident: bib95 article-title: Paracrine and endocrine effects of adipose tissue on cancer development and progression publication-title: Endocr. Rev. – volume: 16 start-page: 1 year: 2016 end-page: 11 ident: bib108 article-title: SGLT2 inhibitors: benefit/risk balance publication-title: Curr. Diabetes Rep. – volume: 19 start-page: 71 year: 2022 ident: bib118 article-title: Antenatal depression among women with gestational diabetes mellitus: a pilot study publication-title: Reprod. Health – volume: 10 start-page: 2 year: 2024 ident: bib96 article-title: Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors publication-title: Cardiooncology – volume: 139 start-page: 163 year: 2018 end-page: 184 ident: bib31 article-title: Gold nanoparticles for the delivery of cancer therapeutics publication-title: Adv. Cancer Res. – volume: 38 start-page: 1218 year: 2015 end-page: 1227 ident: bib21 article-title: Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension publication-title: Diabetes Care – volume: 44 start-page: 693 year: 2023 end-page: 723 ident: bib124 article-title: Insulin/IGF Axis and the receptor for advanced glycation end products: role in meta-inflammation and potential in cancer therapy publication-title: Endocr. Rev. – volume: 21 start-page: 7802 year: 2020 ident: bib103 article-title: NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells publication-title: Int. J. Mol. Sci. – volume: 14 start-page: 754 year: 2014 end-page: 762 ident: bib8 article-title: Cancer cachexia: understanding the molecular basis publication-title: Nat. Rev. Cancer – volume: 8 year: 2017 ident: bib54 article-title: The association between obesity related adipokines and risk of breast cancer: a meta-analysis publication-title: Oncotarget – volume: 1 start-page: 1 year: 2015 end-page: 22 ident: bib34 article-title: Type 2 diabetes mellitus publication-title: Nat. Rev. Dis. Prim. – volume: 12 year: 2020 ident: bib39 article-title: Diabetes as a risk factor for breast cancer publication-title: Cureus – volume: 33 start-page: 2518 year: 2019 end-page: 2530 ident: bib86 article-title: Natural products with SGLT2 inhibitory activity: possibilities of application for the treatment of diabetes publication-title: Phytother Res. – volume: 23 start-page: 3737 year: 2017 ident: bib68 article-title: Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma publication-title: Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.: international medical journal of experimental and clinical research – volume: 19 start-page: 1 year: 2019 end-page: 10 ident: bib109 article-title: The cytotoxic effect and glucose uptake modulation of Baeckea frutescens on breast cancer cells publication-title: BMC Compl. Alternative Med. – volume: 22 start-page: 1444 year: 2021 ident: bib97 article-title: Tumor metabolic reprogramming by adipokines as a critical driver of obesity-associated cancer progression publication-title: Int. J. Mol. Sci. – volume: 17 start-page: 1180 year: 2015 end-page: 1193 ident: bib26 article-title: Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes publication-title: Obes. Metabol. – volume: 350 year: 2015 ident: bib120 article-title: Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies publication-title: Br. Med. J. – volume: 32 start-page: 435 year: 2017 end-page: 443 ident: bib131 article-title: Novel and unexpected functions of SGLTs publication-title: Physiology – volume: 60 start-page: 1022 year: 2017 end-page: 1032 ident: bib23 article-title: Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium publication-title: Diabetologia – volume: 22 start-page: 104 year: 2011 end-page: 112 ident: bib122 article-title: SGLT2 mediates glucose reabsorption in the early proximal tubule publication-title: J. Am. Soc. Nephrol. – volume: 42 start-page: 2846 year: 2021 ident: bib84 article-title: TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines publication-title: Eur. Heart J. – volume: 12 start-page: 2252 year: 2020 ident: bib123 article-title: Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer publication-title: Cancers – year: 2023 ident: bib16 article-title: Therapeutic Potential of Diindolylmethane and Empagliflozin in DMBA-Induced Breast Cancer: on Body Weight and Tumor Volume – volume: 9 start-page: 1380 year: 2020 ident: bib112 article-title: Cancer biology and prevention in diabetes publication-title: Cells – volume: 138 start-page: 557 year: 2018 end-page: 569 ident: bib66 article-title: Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas publication-title: Journal of neuro-oncology – volume: 70 start-page: 741 year: 2010 end-page: 751 ident: bib91 article-title: Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes publication-title: Cancer Res. – volume: 15 start-page: 463 year: 2013 end-page: 473 ident: bib135 article-title: Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease publication-title: Diabetes Obes. Metabol. – volume: 8 start-page: 76 year: 2008 end-page: 87 ident: bib20 article-title: Diabetes mellitus as a risk factor for cancer: stress or viral etiology? publication-title: Infect. Disord. - Drug Targets – volume: 33 start-page: 547 year: 2012 end-page: 594 ident: bib33 article-title: The role of adiponectin in cancer: a review of current evidence publication-title: Endocr. Rev. – volume: 3 start-page: 1330 year: 2020 end-page: 1338 ident: bib41 article-title: Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies publication-title: ACS Pharmacol. Transl. Sci. – volume: 943 year: 2023 ident: bib88 article-title: Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer publication-title: Eur. J. Pharmacol. – volume: 87 start-page: 4 year: 2010 end-page: 14 ident: bib111 article-title: Global estimates of the prevalence of diabetes for 2010 and 2030 publication-title: Diabetes Res. Clin. Pract. – volume: 1874 year: 2020 ident: bib119 article-title: Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer publication-title: Biochim. Biophys. Acta Rev. Canc – volume: 22 start-page: 113 year: 2011 end-page: 123 ident: bib79 article-title: The sweet pee model for Sglt2 mutation publication-title: J. Am. Soc. Nephrol. – volume: 10 start-page: 69 year: 2023 end-page: 82 ident: bib14 article-title: Sodium-glucose transporter (SGLT2) inhibition: a potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds publication-title: Egyptian Journal of Basic and Applied Sciences – year: 2013 ident: bib57 article-title: Full Prescribing Information – volume: 966 year: 2024 ident: bib75 article-title: Investigation of co-treatment multi-targeting approaches in breast cancer cell lines publication-title: Eur. J. Pharmacol. – volume: 11 start-page: 1533 year: 2020 ident: bib30 article-title: Subpopulation targeting of pyruvate dehydrogenase and GLUT1 decouples metabolic heterogeneity during collective cancer cell invasion publication-title: Nat. Commun. – volume: 14 start-page: 127 year: 2023 ident: bib132 article-title: Empagliflozin: a potential anticancer drug publication-title: Discover Oncology – volume: 32 start-page: 817 year: 2024 ident: bib63 article-title: A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells publication-title: Oncology Research – volume: 155 year: 2022 ident: bib105 article-title: Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats publication-title: Biomed. Pharmacother. – volume: 194 year: 2024 ident: bib106 article-title: Non-apoptotic cell death programs in cervical cancer with an emphasis on ferroptosis publication-title: Crit. Rev. Oncol. Hematol. – volume: 38 start-page: 330 year: 2014 ident: bib104 article-title: Hyperglycemia as a risk factor for cancer progression publication-title: Diabetes & metabolism journal – volume: 14 start-page: 5811 year: 2022 ident: bib38 article-title: SGLT-2 inhibitors in cancer treatment—mechanisms of action and emerging new perspectives publication-title: Cancers – volume: 385 start-page: 423 year: 2012 end-page: 436 ident: bib117 article-title: Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo publication-title: N. Schmied. Arch. Pharmacol. – volume: 38 start-page: 350 year: 2020 end-page: 365. e357 ident: bib138 article-title: SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways publication-title: Cancer Cell – volume: 166 year: 2023 ident: bib3 article-title: Optimal control strategies for SGLT2 inhibitors as a novel anti-tumor agent and their effect on human breast cancer cells with the effect of time delay and hyperglycemia publication-title: Comput. Biol. Med. – volume: 118 start-page: 71 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib43 article-title: Pharmacological aspects of the safety of gliflozins publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2016.07.001 – start-page: 251 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib9 article-title: Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data publication-title: Breast Cancer – volume: 22 start-page: 104 year: 2011 ident: 10.1016/j.ejphar.2024.176803_bib122 article-title: SGLT2 mediates glucose reabsorption in the early proximal tubule publication-title: J. Am. Soc. Nephrol. doi: 10.1681/ASN.2010030246 – volume: 131 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib93 article-title: Type II diabetes mellitus: a review on recent drug based therapeutics publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2020.110708 – volume: 18 start-page: 62 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib62 article-title: SGLT2 inhibitors in patients with chronic kidney disease and heart disease: a literature review publication-title: Methodist DeBakey Cardiovascular Journal doi: 10.14797/mdcvj.1120 – volume: 78 start-page: 513 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib82 article-title: Ertugliflozin: first global approval publication-title: Drugs doi: 10.1007/s40265-018-0878-6 – volume: 15 start-page: 463 year: 2013 ident: 10.1016/j.ejphar.2024.176803_bib135 article-title: Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease publication-title: Diabetes Obes. Metabol. doi: 10.1111/dom.12090 – volume: 67 start-page: 99 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib67 article-title: SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation publication-title: Endocr. J. doi: 10.1507/endocrj.EJ19-0428 – volume: 7 year: 2012 ident: 10.1016/j.ejphar.2024.176803_bib139 article-title: Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin publication-title: PLoS One doi: 10.1371/journal.pone.0049513 – volume: 79 start-page: S14 year: 2011 ident: 10.1016/j.ejphar.2024.176803_bib58 article-title: SGLT2 inhibitors: molecular design and potential differences in effect publication-title: Kidney Int. doi: 10.1038/ki.2010.511 – volume: 5 start-page: 1048 year: 2016 ident: 10.1016/j.ejphar.2024.176803_bib126 article-title: The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration publication-title: Mol. Metabol. doi: 10.1016/j.molmet.2016.08.014 – volume: 8 start-page: 76 year: 2008 ident: 10.1016/j.ejphar.2024.176803_bib20 article-title: Diabetes mellitus as a risk factor for cancer: stress or viral etiology? publication-title: Infect. Disord. - Drug Targets doi: 10.2174/187152608784746501 – volume: 13 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib143 article-title: The relationship between diabetes mellitus and cancers and its underlying mechanisms publication-title: Front. Endocrinol. – volume: 23 start-page: 391 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib94 article-title: Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin publication-title: Neoplasia doi: 10.1016/j.neo.2021.02.003 – volume: 32 start-page: 435 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib131 article-title: Novel and unexpected functions of SGLTs publication-title: Physiology doi: 10.1152/physiol.00021.2017 – volume: 14 start-page: 5811 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib38 article-title: SGLT-2 inhibitors in cancer treatment—mechanisms of action and emerging new perspectives publication-title: Cancers doi: 10.3390/cancers14235811 – year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib134 article-title: Diabetes and incidence of breast cancer and its molecular subtypes: a systematic review and meta-analysis publication-title: medRxiv, 2023.2005. 2013.23289893 – volume: 43 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib77 article-title: Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence publication-title: Redox Biol. doi: 10.1016/j.redox.2021.102006 – volume: 16 start-page: 1538 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib5 article-title: From diabetes to Oncology: glucagon-like peptide-1 (GLP-1) receptor agonist's dual role in prostate cancer publication-title: Cancers doi: 10.3390/cancers16081538 – volume: 12 start-page: 154 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib11 article-title: Targeting glucose transporters for breast cancer therapy: the effect of natural and synthetic compounds publication-title: Cancers doi: 10.3390/cancers12010154 – volume: 10 start-page: 2 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib96 article-title: Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors publication-title: Cardiooncology – volume: 14 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib85 article-title: GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway publication-title: Front. Immunol. doi: 10.3389/fimmu.2023.1163288 – volume: 13 start-page: 4184 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib98 article-title: Glucose transporters as a target for anticancer therapy publication-title: Cancers doi: 10.3390/cancers13164184 – year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib6 – volume: 37 start-page: 610 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib37 article-title: Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor publication-title: Clin. Therapeut. doi: 10.1016/j.clinthera.2014.12.013 – volume: 5 start-page: 478 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib2 article-title: A precision medicine approach to metabolic therapy for breast cancer in mice publication-title: Commun. Biol. doi: 10.1038/s42003-022-03422-9 – volume: 13 start-page: 2213 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib15 article-title: Adiponectin: a promising target for the treatment of diabetes and its complications publication-title: Life doi: 10.3390/life13112213 – volume: 155 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib105 article-title: Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2022.113675 – volume: 12 start-page: 2252 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib123 article-title: Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer publication-title: Cancers doi: 10.3390/cancers12082252 – volume: 42 start-page: 2846 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib84 article-title: TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehab724.2846 – volume: 132 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib142 article-title: Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2020.110821 – volume: 184 start-page: 4 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib29 article-title: Is cancer a metabolic disease? publication-title: Am. J. Pathol. doi: 10.1016/j.ajpath.2013.07.035 – volume: 1 start-page: 329 year: 2009 ident: 10.1016/j.ejphar.2024.176803_bib27 article-title: Targeting the adiponectin: leptin ratio for postmenopausal breast cancer prevention publication-title: Front. Biosci. doi: 10.2741/s30 – volume: 130 start-page: 72 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib45 article-title: SGLT2 inhibitors: are they safe? publication-title: PGM (Postgrad. Med.) doi: 10.1080/00325481.2018.1394152 – volume: 39 start-page: S165 year: 2016 ident: 10.1016/j.ejphar.2024.176803_bib46 article-title: SGLT2 inhibitors and the diabetic kidney publication-title: Diabetes Care doi: 10.2337/dcS15-3006 – volume: 98 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib137 article-title: Association of serum adiponectin with breast cancer: a meta-analysis of 27 case-control studies publication-title: Medicine – volume: 25 start-page: 253 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib12 article-title: Exploring the role of sodium-glucose cotransporter as a new target for cancer therapy publication-title: J. Pharm. Pharmaceut. Sci. – volume: 18 start-page: 123 year: 2012 ident: 10.1016/j.ejphar.2024.176803_bib114 article-title: Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis publication-title: Pathol. Oncol. Res. doi: 10.1007/s12253-011-9466-8 – volume: 113 start-page: E4966 year: 2016 ident: 10.1016/j.ejphar.2024.176803_bib136 – volume: 33 start-page: 547 year: 2012 ident: 10.1016/j.ejphar.2024.176803_bib33 article-title: The role of adiponectin in cancer: a review of current evidence publication-title: Endocr. Rev. doi: 10.1210/er.2011-1015 – volume: 33 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib129 article-title: The effect of sodium glucose transporter 2 inhibitors on proliferation and growth factor signaling pathways in triple negative breast cancer publication-title: Faseb. J. doi: 10.1096/fasebj.2019.33.1_supplement.647.48 – volume: 9 start-page: 1380 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib112 article-title: Cancer biology and prevention in diabetes publication-title: Cells doi: 10.3390/cells9061380 – volume: 10 start-page: 1548 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib72 article-title: SLC25A18 has prognostic value in colorectal cancer and represses Warburg effect and cell proliferation via Wnt signaling publication-title: Am. J. Cancer Res. – volume: 11 start-page: 1867 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib13 article-title: SGLT2 inhibitors as potential anticancer agents publication-title: Biomedicines doi: 10.3390/biomedicines11071867 – year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib16 – volume: 355 start-page: 854 year: 2000 ident: 10.1016/j.ejphar.2024.176803_bib69 article-title: UK medicines information publication-title: Lancet doi: 10.1016/S0140-6736(05)72477-6 – volume: 943 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib88 article-title: Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2023.175565 – volume: 47 start-page: 125 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib127 article-title: SGLT2 inhibitor use and risk of breast cancer among adult women with type 2 diabetes publication-title: Drug Saf. doi: 10.1007/s40264-023-01373-6 – volume: 12 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib39 article-title: Diabetes as a risk factor for breast cancer publication-title: Cureus – volume: 138 start-page: 557 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib66 article-title: Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas publication-title: Journal of neuro-oncology doi: 10.1007/s11060-018-2823-7 – volume: 74 start-page: 611 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib99 article-title: Ipragliflozin: first global approval publication-title: Drugs doi: 10.1007/s40265-014-0204-x – volume: 12 start-page: 816 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib144 article-title: Insulin-like growth factor II: an essential adult stem cell niche constituent in brain and intestine publication-title: Stem Cell Rep. doi: 10.1016/j.stemcr.2019.02.011 – volume: 93 start-page: 244 year: 2016 ident: 10.1016/j.ejphar.2024.176803_bib80 article-title: Sodium glucose CoTransporter 2 (SGLT2) inhibitors: current status and future perspective publication-title: Eur. J. Pharmaceut. Sci. doi: 10.1016/j.ejps.2016.08.025 – volume: 11 start-page: 1533 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib30 article-title: Subpopulation targeting of pyruvate dehydrogenase and GLUT1 decouples metabolic heterogeneity during collective cancer cell invasion publication-title: Nat. Commun. doi: 10.1038/s41467-020-15219-7 – year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib4 article-title: Optimal control strategies for SGLT2 inhibitors as a novel anti-tumor agent and their effect on human breast cancer cells with the effect of time delay and hyperglycemia risk factor publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2023.107552 – volume: 74 start-page: 945 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib83 article-title: Luseogliflozin: first global approval publication-title: Drugs doi: 10.1007/s40265-014-0230-8 – volume: 1 start-page: 1 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib34 article-title: Type 2 diabetes mellitus publication-title: Nat. Rev. Dis. Prim. – volume: 12 start-page: 78 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib50 article-title: Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences publication-title: Diabetes Vasc. Dis. Res. doi: 10.1177/1479164114561992 – volume: 17 start-page: 1180 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib26 article-title: Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes publication-title: Obes. Metabol. doi: 10.1111/dom.12572 – volume: 39 start-page: 3028 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib65 article-title: Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer publication-title: Oncogene doi: 10.1038/s41388-020-1202-y – volume: 6 start-page: 27 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib70 article-title: How does mTOR sense glucose starvation? AMPK is the usual suspect publication-title: Cell death discovery doi: 10.1038/s41420-020-0260-9 – year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib48 – volume: 33 start-page: 2518 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib86 article-title: Natural products with SGLT2 inhibitory activity: possibilities of application for the treatment of diabetes publication-title: Phytother Res. doi: 10.1002/ptr.6421 – volume: 348 start-page: 1625 year: 2003 ident: 10.1016/j.ejphar.2024.176803_bib18 article-title: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa021423 – volume: 6 start-page: 357 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib102 article-title: Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’ publication-title: Diabetes Therapy doi: 10.1007/s13300-015-0128-9 – volume: 1874 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib119 article-title: Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer publication-title: Biochim. Biophys. Acta Rev. Canc – volume: 527 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib71 article-title: Diversity of insulin and IGF signaling in breast cancer: implications for therapy publication-title: Mol. Cell. Endocrinol. doi: 10.1016/j.mce.2021.111213 – volume: 32 start-page: 550 year: 2011 ident: 10.1016/j.ejphar.2024.176803_bib95 article-title: Paracrine and endocrine effects of adipose tissue on cancer development and progression publication-title: Endocr. Rev. doi: 10.1210/er.2010-0030 – volume: 16 start-page: 1 year: 2016 ident: 10.1016/j.ejphar.2024.176803_bib108 article-title: SGLT2 inhibitors: benefit/risk balance publication-title: Curr. Diabetes Rep. doi: 10.1007/s11892-016-0789-4 – volume: 194 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib106 article-title: Non-apoptotic cell death programs in cervical cancer with an emphasis on ferroptosis publication-title: Crit. Rev. Oncol. Hematol. doi: 10.1016/j.critrevonc.2023.104249 – volume: 15 start-page: 4250 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib17 article-title: Role of leptin and adiponectin in carcinogenesis publication-title: Cancers doi: 10.3390/cancers15174250 – volume: 8 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib54 article-title: The association between obesity related adipokines and risk of breast cancer: a meta-analysis publication-title: Oncotarget doi: 10.18632/oncotarget.17853 – volume: 70 start-page: 741 year: 2010 ident: 10.1016/j.ejphar.2024.176803_bib91 article-title: Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-2141 – volume: 27 start-page: 50 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib110 article-title: Diabetes and overall survival among breast cancer patients in the US military health system publication-title: Cancer Epidemiol. Biomarkers Prev. doi: 10.1158/1055-9965.EPI-17-0439 – volume: 38 start-page: 350 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib138 article-title: SETD2 restricts prostate cancer metastasis by integrating EZH2 and AMPK signaling pathways publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.05.022 – volume: 14 start-page: 754 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib8 article-title: Cancer cachexia: understanding the molecular basis publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3829 – volume: 146 start-page: 712 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib53 article-title: Diabetes and cancer risk: a Mendelian randomization study publication-title: Int. J. Cancer doi: 10.1002/ijc.32310 – volume: 19 start-page: 71 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib118 article-title: Antenatal depression among women with gestational diabetes mellitus: a pilot study publication-title: Reprod. Health doi: 10.1186/s12978-022-01374-1 – volume: 61 start-page: 2140 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib92 article-title: Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events publication-title: Diabetologia doi: 10.1007/s00125-018-4664-5 – volume: 14 start-page: 127 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib132 article-title: Empagliflozin: a potential anticancer drug publication-title: Discover Oncology doi: 10.1007/s12672-023-00719-x – year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib73 article-title: Glycosylation in breast cancer progression and mammary development: molecular connections and malignant transformations publication-title: Life Sci. doi: 10.1016/j.lfs.2023.121781 – volume: 9 start-page: 367 year: 2008 ident: 10.1016/j.ejphar.2024.176803_bib55 article-title: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm2391 – volume: 32 start-page: 817 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib63 article-title: A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells publication-title: Oncology Research doi: 10.32604/or.2024.048988 – volume: 17 start-page: 1411 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib25 article-title: Subventricular zone adult mouse neural stem cells require insulin receptor for self-renewal publication-title: Stem Cell Rep. doi: 10.1016/j.stemcr.2022.04.007 – volume: 60 start-page: 890 year: 2011 ident: 10.1016/j.ejphar.2024.176803_bib60 article-title: SGLT2 deletion improves glucose homeostasis and preserves pancreatic β-cell function publication-title: Diabetes doi: 10.2337/db10-1328 – ident: 10.1016/j.ejphar.2024.176803_bib113 – volume: 114 start-page: 716 year: 2016 ident: 10.1016/j.ejphar.2024.176803_bib51 article-title: From obesity to diabetes and cancer: epidemiological links and role of therapies publication-title: Br. J. Cancer doi: 10.1038/bjc.2016.37 – volume: 43 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib78 article-title: Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence publication-title: Redox Biol. doi: 10.1016/j.redox.2021.102006 – volume: 18 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib32 article-title: Repurposing SGLT2 inhibitors publication-title: Nat. Rev. Drug Discov. – year: 2013 ident: 10.1016/j.ejphar.2024.176803_bib57 – volume: 85 start-page: 972 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib141 article-title: Influence of diabetes mellitus on mortality in breast cancer patients publication-title: ANZ J. Surg. doi: 10.1111/ans.12877 – volume: 79 start-page: 4855 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib42 article-title: Dual inhibition of GLUT1 and the ATR/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-18-3959 – volume: 142 start-page: 1712 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib61 article-title: Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake publication-title: Int. J. Cancer doi: 10.1002/ijc.31193 – volume: 166 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib3 article-title: Optimal control strategies for SGLT2 inhibitors as a novel anti-tumor agent and their effect on human breast cancer cells with the effect of time delay and hyperglycemia publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2023.107552 – volume: 60 start-page: 1022 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib23 article-title: Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium publication-title: Diabetologia doi: 10.1007/s00125-017-4229-z – volume: 22 start-page: 113 year: 2011 ident: 10.1016/j.ejphar.2024.176803_bib79 article-title: The sweet pee model for Sglt2 mutation publication-title: J. Am. Soc. Nephrol. doi: 10.1681/ASN.2010080888 – volume: 19 start-page: 1 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib109 article-title: The cytotoxic effect and glucose uptake modulation of Baeckea frutescens on breast cancer cells publication-title: BMC Compl. Alternative Med. – volume: 24 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib1 article-title: Diabetes and cancer: a comprehensive review publication-title: J. Res. Med. Sci.: The Official Journal of Isfahan University of Medical Sciences doi: 10.4103/jrms.JRMS_242_19 – volume: 264 start-page: 247 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib130 article-title: Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment publication-title: J. Contr. Release doi: 10.1016/j.jconrel.2017.09.003 – volume: 38 start-page: 412 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib56 article-title: Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study publication-title: Diabetes Care doi: 10.2337/dc13-2955 – volume: 12 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib74 article-title: Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis publication-title: Front. Pharmacol. doi: 10.3389/fphar.2021.752440 – year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib49 – volume: 23 start-page: 3737 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib68 article-title: Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma publication-title: Med. Sci. Mon. Int. Med. J. Exp. Clin. Res.: international medical journal of experimental and clinical research – volume: 14 start-page: 460 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib24 article-title: Ferroptosis as a potential target for cancer therapy publication-title: Cell Death Dis. doi: 10.1038/s41419-023-05930-w – volume: 966 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib75 article-title: Investigation of co-treatment multi-targeting approaches in breast cancer cell lines publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2024.176328 – ident: 10.1016/j.ejphar.2024.176803_bib101 – volume: 95 start-page: 659 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib22 article-title: Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients publication-title: Arch. Toxicol. doi: 10.1007/s00204-020-02951-8 – volume: 3 start-page: 1330 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib41 article-title: Empagliflozin and doxorubicin synergistically inhibit the survival of triple-negative breast cancer cells via interfering with the mTOR pathway and inhibition of calmodulin: in vitro and molecular docking studies publication-title: ACS Pharmacol. Transl. Sci. doi: 10.1021/acsptsci.0c00144 – volume: 21 start-page: 7802 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib103 article-title: NLRP3 as putative marker of ipilimumab-induced cardiotoxicity in the presence of hyperglycemia in estrogen-responsive and triple-negative breast cancer cells publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms21207802 – volume: 10 start-page: 69 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib14 article-title: Sodium-glucose transporter (SGLT2) inhibition: a potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds publication-title: Egyptian Journal of Basic and Applied Sciences doi: 10.1080/2314808X.2022.2145734 – volume: 16 start-page: 1103 year: 2009 ident: 10.1016/j.ejphar.2024.176803_bib125 article-title: Diabetes and cancer publication-title: Endocr. Relat. Cancer doi: 10.1677/ERC-09-0087 – volume: 118 start-page: 394 year: 2017 ident: 10.1016/j.ejphar.2024.176803_bib28 article-title: Roles of adiponectin and leptin as diagnostic markers in pancreatic cancer publication-title: Bratisl. Lek. Listy – volume: 5 start-page: 161 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib81 article-title: Sodium glucose co-transporter inhibitors–A new class of old drugs publication-title: International Journal of Applied and Basic Medical Research doi: 10.4103/2229-516X.165363 – volume: 14 start-page: 574 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib10 article-title: Oral contraceptive use and breast cancer risk according to molecular subtypes status: a systematic review and meta-analysis of case-control studies publication-title: Cancers doi: 10.3390/cancers14030574 – volume: 112 start-page: E4111 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib107 article-title: Functional expression of sodium-glucose transporters in cancer publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1511698112 – volume: 15 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib116 article-title: Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential publication-title: Front. Pharmacol. – volume: 10 start-page: 52 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib121 article-title: An in-vitro and in silico anticancer study of FDA approved antidiabetic drugs glimepiride and empagliflozin publication-title: Int. J. Pharma Bio Sci. – volume: 92 start-page: 136 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib76 article-title: Burden of cancer attributable to obesity, type 2 diabetes and associated risk factors publication-title: Metabolism doi: 10.1016/j.metabol.2018.10.013 – start-page: 549 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib7 – volume: 139 start-page: 163 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib31 article-title: Gold nanoparticles for the delivery of cancer therapeutics publication-title: Adv. Cancer Res. doi: 10.1016/bs.acr.2018.05.001 – volume: 87 start-page: 4 year: 2010 ident: 10.1016/j.ejphar.2024.176803_bib111 article-title: Global estimates of the prevalence of diabetes for 2010 and 2030 publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2009.10.007 – volume: 350 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib120 article-title: Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies publication-title: Br. Med. J. – volume: 13 year: 2022 ident: 10.1016/j.ejphar.2024.176803_bib133 article-title: Emerging roles of sodium glucose cotransporter 2 (SGLT-2) inhibitors in diabetic cardiovascular diseases: focusing on immunity, inflammation and metabolism publication-title: Front. Pharmacol. – volume: 33 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib140 article-title: HCAR1/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.108487 – volume: 9 start-page: 125 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib19 article-title: The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer publication-title: Cell Death Dis. doi: 10.1038/s41419-017-0140-2 – start-page: 1637 year: 2018 ident: 10.1016/j.ejphar.2024.176803_bib36 article-title: Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes publication-title: Therapeut. Clin. Risk Manag. doi: 10.2147/TCRM.S137068 – volume: 153 start-page: 519 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib59 article-title: Exogenous normal mammary epithelial mitochondria suppress glycolytic metabolism and glucose uptake of human breast cancer cells publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-015-3583-0 – volume: 385 start-page: 423 year: 2012 ident: 10.1016/j.ejphar.2024.176803_bib117 article-title: Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo publication-title: N. Schmied. Arch. Pharmacol. doi: 10.1007/s00210-011-0713-z – volume: 373 start-page: 2117 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib145 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504720 – volume: 38 start-page: 1218 year: 2015 ident: 10.1016/j.ejphar.2024.176803_bib21 article-title: Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension publication-title: Diabetes Care doi: 10.2337/dc14-0315 – volume: 22 start-page: 1444 year: 2021 ident: 10.1016/j.ejphar.2024.176803_bib97 article-title: Tumor metabolic reprogramming by adipokines as a critical driver of obesity-associated cancer progression publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms22031444 – volume: 8 start-page: 1 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib87 article-title: Fructose contributes to the Warburg effect for cancer growth publication-title: Cancer Metabol. doi: 10.1186/s40170-020-00222-9 – volume: 59 start-page: 949 year: 2020 ident: 10.1016/j.ejphar.2024.176803_bib44 article-title: Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor publication-title: Clin. Pharmacokinet. doi: 10.1007/s40262-020-00875-1 – volume: 74 start-page: 939 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib100 article-title: Tofogliflozin: first global approval publication-title: Drugs doi: 10.1007/s40265-014-0229-1 – volume: 47 start-page: 111 year: 1998 ident: 10.1016/j.ejphar.2024.176803_bib35 article-title: Insulin and related factors in premenopausal breast cancer risk publication-title: Breast Cancer Res. Treat. doi: 10.1023/A:1005831013718 – volume: 43 start-page: 733 year: 2019 ident: 10.1016/j.ejphar.2024.176803_bib115 article-title: Diabetes and cancer: cancer should be screened in routine diabetes assessment publication-title: Diabetes & metabolism journal doi: 10.4093/dmj.2019.0177 – volume: 38 start-page: 330 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib104 article-title: Hyperglycemia as a risk factor for cancer progression publication-title: Diabetes & metabolism journal doi: 10.4093/dmj.2014.38.5.330 – year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib47 – volume: 32 start-page: 817 year: 2024 ident: 10.1016/j.ejphar.2024.176803_bib64 article-title: A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells publication-title: Oncol. Res. doi: 10.32604/or.2024.048988 – volume: 16 start-page: 97 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib52 article-title: Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes publication-title: Obes. Metabol. doi: 10.1111/dom.12124 – volume: 44 start-page: 693 year: 2023 ident: 10.1016/j.ejphar.2024.176803_bib124 article-title: Insulin/IGF Axis and the receptor for advanced glycation end products: role in meta-inflammation and potential in cancer therapy publication-title: Endocr. Rev. doi: 10.1210/endrev/bnad005 – volume: 11 start-page: 1335 year: 2014 ident: 10.1016/j.ejphar.2024.176803_bib89 article-title: Update on developments with SGLT2 inhibitors in the management of type 2 diabetes publication-title: Drug Des. Dev. Ther. doi: 10.2147/DDDT.S50773 |
| SSID | ssj0005925 |
| Score | 2.5328605 |
| SecondaryResourceType | review_article |
| Snippet | The link between type 2 diabetes mellitus (T2DM) and an increased risk of breast cancer (BC) has prompted the exploration of novel therapeutic strategies... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 176803 |
| SubjectTerms | Animals Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Breast neoplasms Breast Neoplasms - drug therapy Clinical Trials as Topic Diabetes mellitus Female Gene mutations Humans Precision medicine SGLT2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use |
| Title | Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies |
| URI | https://dx.doi.org/10.1016/j.ejphar.2024.176803 https://www.ncbi.nlm.nih.gov/pubmed/38950839 https://www.proquest.com/docview/3074725975 |
| Volume | 978 |
| WOSCitedRecordID | wos001266292000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect Freedom Collection 2021 customDbUrl: eissn: 1879-0712 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005925 issn: 0014-2999 databaseCode: AIEXJ dateStart: 19950105 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9owFLZou4e9TLuXXSpPmnihQY2TkPgRTXRbhRjSUok9RcfYEWElMKBd11-0nznf4jC1VbuHvUTBcS7k-zgc2-ecD6H3RxRCllPw1BqWF3YD4TGaCFXGVUCX-DwnTItNxMNhMh7TUaPxu8qFuTiLyzK5vKTL_wq1bJNgq9TZf4DbXVQ2yH0JutxK2OX2XsDXUXXKp5QvrvAmCtpVe7nYqNgg435-_ThISbsopwUrtOJOUbaZilDftG33OgZdRZqvhOeyKHUunEup3IpEvGmK37q7y7pGtpvFH4Io5lfAhZ7b-QZrmNdkTWHG4Pt0rY_15oWLIh7qMrMm0WhawpWjoFoT0BrF7RPIYbU9oUFCHbEVbdngJNZ5VcZIixvarOGmRvzHml5fDpx0uYTr_wpmgmLWETP1XTvqpp26-99FuIdfsuPTwSBL--O0tfzhKX0ytY5vxVp20B6JIyrt517vc398UocTUS3w6x60StPUsYTXb3ybG3TbMEe7O-lj9MiOU3DP8OsJaojyKWqNDIi_DnFa5-2tD3ELj7bgfYZ-OhJiSUK8RULsSIgXOdYkxDUJ5S42JMS2uyOhOrRNQnlRjt0HS8Ln6PS4n3745FmJD28iPaeN53PCWU4CQQSPCCh_E44CDtLrDIDnfhTHPOLS5Rc-ZSIKuNJzjaRfyghANw-DF2i3XJRiH2EKCeW-KrsdspDGggEJIwi6nMUkCCbQREH1xrOJrX-vZFjOsirQcZYZnDKFU2ZwaiLPnbU09V_u6B9XYGbWhzW-aSbJeMeZ7yrsM2ni1bodlGJxvs4CJXJB5Mg_aqKXhhTuWeR4Qwk60Ff3OPs1elj_3t6g3c3qXLxFDyYXm2K9OkA78Tg5sLT-A_Ok1nM |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploring+the+anti-cancer+potential+of+SGLT2+inhibitors+in+breast+cancer+treatment+in+pre-clinical+and+clinical+studies&rft.jtitle=European+journal+of+pharmacology&rft.au=Naeimzadeh%2C+Yasaman&rft.au=Tajbakhsh%2C+Amir&rft.au=Nemati%2C+Mahnaz&rft.au=Fallahi%2C+Jafar&rft.date=2024-09-05&rft.issn=1879-0712&rft.eissn=1879-0712&rft.volume=978&rft.spage=176803&rft_id=info:doi/10.1016%2Fj.ejphar.2024.176803&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2999&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2999&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2999&client=summon |